Comparative prostate MRI before and after chronic granulomatous prostatitis following intravesical bacillus Calmette-Guérin therapy.
| Autor: | Sarkis J; Department of Urology, Hôtel-Dieu de France Hospital, Beirut, Lebanon., Nawfal G; Department of Radiology, Saint Joseph Hospital, Beirut, Lebanon., El-Haddad E; Department of Radiology, Hôtel-Dieu de France Hospital, Beirut, Lebanon., Tayeh GA; Department of Urology, Hôtel-Dieu de France Hospital, Beirut, Lebanon., Mahfoud N; Department of Pathology, Saint Joseph Hospital, Beirut, Lebanon., Sarkis P; Department of Urology, Saint Joseph Hospital, Beirut, Lebanon. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Future science OA [Future Sci OA] 2020 Oct 20; Vol. 7 (2), pp. FSO637. Date of Electronic Publication: 2020 Oct 20. |
| DOI: | 10.2144/fsoa-2020-0065 |
| Abstrakt: | Background: Granulomatous prostatitis (GnP) is an interesting complication of bacillus Calmette-Guérin (BCG) therapy as it mimics prostate cancer on clinical, biochemical and imaging examinations. In the era of multiparametric prostate MRI (mpMRI), differentiation of GnP from prostate cancer on imaging is essential. Case Presentation: We report a case of post-BCG GnP in a patient with nonmuscle invasive bladder cancer, presenting with a prostate-specific antigen level of 21.6 ng/ml and prostate imaging reporting and data system (PI-RADS) 5 peripheral lesions. A mpMRI performed 6 months before showed a score 2 of PI-RADS. Conclusion: The comparison of mpMRI images before and after BCG administration gives urologists, oncologists and radiologists a precise idea of the mpMRI changes that occur following BCG administration to eventually prevent unnecessary biopsies in future patients. Competing Interests: Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript. (© 2020 Julien Sarkis.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|